Poly I-C
In clinical developmentAlso known as POLYINOSINIC-POLYCYTIDYLIC ACID (HIGH MW), POLYINOSINIC-POLYCYTIDYLIC ACID (LOW MW), Polyinosinic polycytidylic acid, Polyinosinic-polycytidylic acid+3 more
POLYINOSINIC-POLYCYTIDYLIC ACID (HIGH MW), POLYINOSINIC-POLYCYTIDYLIC ACID (LOW MW), Polyinosinic polycytidylic acid, Polyinosinic-polycytidylic acid, Polyinosinic-polycytidylic acid complex, Poly(I+C), PolyIC.
Recent clinical, regulatory, research and industry developments relating to this drug.
Trial watch: TLR3 agonists in cancer therapy.
Maternal immune activation alters fetal brain development through interleukin-6.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes5
Journals, researchers & institutions
- EMBO molecular medicine1
- Oncoimmunology1
- The Journal of neuroscience : the official journal of the Society for Neuroscience1
- Aguado È1
- Bigger BW1
- Boutin H1
- Ellison S1
- Forte G1
- Galluzzi L1
- Garbett K1
- Holley RJ1
- California Institute of Technology1
- Caryl and Israel Englander Institute for Precision Medicine1
- Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 14281
- Centre for Regenerative Medicine1
- Geoffrey Jefferson Brain Research Centre1
- Karolinska Institute1
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials